KR20150119924A - 백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계 - Google Patents
백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계 Download PDFInfo
- Publication number
- KR20150119924A KR20150119924A KR1020157025458A KR20157025458A KR20150119924A KR 20150119924 A KR20150119924 A KR 20150119924A KR 1020157025458 A KR1020157025458 A KR 1020157025458A KR 20157025458 A KR20157025458 A KR 20157025458A KR 20150119924 A KR20150119924 A KR 20150119924A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- aryl
- pharmaceutically acceptable
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 BC(C1*)OC(CO)C1(C)O Chemical compound BC(C1*)OC(CO)C1(C)O 0.000 description 1
- CJCYTUJOSMYXLE-VYOLEAORSA-N CC(C)OC(OCSP(OC[C@H](C(C1)O)O[C@H]1[n]1c(ncnc2N)c2nc1)(O[C@@H]([C@@H](CO)O[C@H]1N(C=CC(N2)=O)C2=O)C1OC)=O)=O Chemical compound CC(C)OC(OCSP(OC[C@H](C(C1)O)O[C@H]1[n]1c(ncnc2N)c2nc1)(O[C@@H]([C@@H](CO)O[C@H]1N(C=CC(N2)=O)C2=O)C1OC)=O)=O CJCYTUJOSMYXLE-VYOLEAORSA-N 0.000 description 1
- LYMICVBGNUEHGE-LIPSAAIPSA-N COC1[C@H](N(C=CC(N2)=O)C2=O)O[C@H](CO)[C@@H]1OP(OC[C@H](C(C1)O)O[C@H]1[n]1c(ncnc2N)c2nc1)(S)=O Chemical compound COC1[C@H](N(C=CC(N2)=O)C2=O)O[C@H](CO)[C@@H]1OP(OC[C@H](C(C1)O)O[C@H]1[n]1c(ncnc2N)c2nc1)(S)=O LYMICVBGNUEHGE-LIPSAAIPSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766011P | 2013-02-18 | 2013-02-18 | |
| US61/766,011 | 2013-02-18 | ||
| PCT/US2014/016996 WO2014127378A2 (en) | 2013-02-18 | 2014-02-18 | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150119924A true KR20150119924A (ko) | 2015-10-26 |
Family
ID=51354704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157025458A Withdrawn KR20150119924A (ko) | 2013-02-18 | 2014-02-18 | 백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10391166B2 (https=) |
| EP (1) | EP2956145A4 (https=) |
| JP (2) | JP6502267B2 (https=) |
| KR (1) | KR20150119924A (https=) |
| CN (1) | CN105992587A (https=) |
| AU (1) | AU2014217892B2 (https=) |
| CA (1) | CA2899599A1 (https=) |
| WO (1) | WO2014127378A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3317290A4 (en) * | 2015-07-02 | 2019-04-10 | Spring Bank Pharmaceuticals, Inc. | COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION |
| TW201717968A (zh) * | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導rig-i和其他模式辨識受體之化合物及組成物 |
| WO2018013887A1 (en) * | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| MX2019000660A (es) * | 2016-07-15 | 2019-10-02 | Sperovie Biosciences Inc | Compuestos, composiciones y métodos para el tratamiento de enfermedades. |
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ-スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| KR102765806B1 (ko) * | 2017-09-05 | 2025-02-10 | 블랙손 테라퓨틱스, 인크. | 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법 |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| KR20210010873A (ko) * | 2018-05-04 | 2021-01-28 | 유비아이 아이피 홀딩스 | 제한된 t 세포 염증 반응으로 표적화된 항체 생산을 용이하게 하는 인공 무차별적 t 헬퍼 세포 에피토프 |
| WO2021040439A1 (ko) * | 2019-08-28 | 2021-03-04 | 주식회사 엔에이백신연구소 | 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물 |
| WO2021046426A1 (en) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| GB2471806B (en) * | 2008-04-03 | 2012-12-19 | Spring Bank Pharmaceuticals Inc | Compositions and methods for treating viral infections |
| KR101926419B1 (ko) * | 2010-08-30 | 2018-12-10 | 스프링 뱅크 파마슈티칼스, 인크. | 치료제로서 올리고뉴클레오타이드 유사체의 설계 |
-
2014
- 2014-02-18 EP EP14750982.2A patent/EP2956145A4/en not_active Withdrawn
- 2014-02-18 KR KR1020157025458A patent/KR20150119924A/ko not_active Withdrawn
- 2014-02-18 CN CN201480009224.7A patent/CN105992587A/zh active Pending
- 2014-02-18 US US14/767,113 patent/US10391166B2/en not_active Expired - Fee Related
- 2014-02-18 CA CA2899599A patent/CA2899599A1/en not_active Abandoned
- 2014-02-18 JP JP2015558212A patent/JP6502267B2/ja not_active Expired - Fee Related
- 2014-02-18 WO PCT/US2014/016996 patent/WO2014127378A2/en not_active Ceased
- 2014-02-18 AU AU2014217892A patent/AU2014217892B2/en not_active Ceased
-
2018
- 2018-02-26 JP JP2018031870A patent/JP2018087243A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016513113A (ja) | 2016-05-12 |
| EP2956145A4 (en) | 2016-08-17 |
| JP2018087243A (ja) | 2018-06-07 |
| WO2014127378A2 (en) | 2014-08-21 |
| US20150374816A1 (en) | 2015-12-31 |
| AU2014217892A1 (en) | 2015-08-13 |
| US10391166B2 (en) | 2019-08-27 |
| JP6502267B2 (ja) | 2019-04-17 |
| WO2014127378A8 (en) | 2014-10-02 |
| AU2014217892B2 (en) | 2018-11-22 |
| EP2956145A2 (en) | 2015-12-23 |
| CN105992587A (zh) | 2016-10-05 |
| CA2899599A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6502267B2 (ja) | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 | |
| KR101926419B1 (ko) | 치료제로서 올리고뉴클레오타이드 유사체의 설계 | |
| KR101620394B1 (ko) | 바이러스 감염증을 치료하기 위한 조성물 및 방법 | |
| CN1257912C (zh) | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 | |
| US9085599B2 (en) | 2′allene-substituted nucleoside derivatives | |
| US9675632B2 (en) | Nucleoside and nucleotide derivatives | |
| HK1229263A (en) | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents | |
| HK1229263A1 (en) | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents | |
| CN1911237A (zh) | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 | |
| HK1198516B (en) | Compositions and methods for treating viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150916 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190218 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20200206 |
|
| WITB | Written withdrawal of application |